Secarna Pharmaceuticals Demonstrates Therapeutic Activity of LNAplus™ ASO Targeting NLRP3 in Autoinflammatory Diseases

Secarna Pharmaceuticals, a biopharmaceutical company specializing in antisense oligonucleotide (ASO) therapies, has published new preclinical data in The Journal of Immunology. The data demonstrates the potent therapeutic activity of their LNAplus(TM) ASO targeting NLRP3 in debilitating autoinflammatory diseases. NLRP3 is a central component of the inflammasome pathway, which is overactive in ma..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms

FDA Action Alert: Argenx, Aldeyra, Intercept and Sarepta

The FDA is set to make four important decisions this week, including the approval of Argenx’s subcutaneous efgartigimod for adults with generalized myasthenia gravis, Aldeyra’s investigational intravitreal injection ADX-2191 for primary vitreoretinal lymphoma, Intercept Pharmaceuticals’ obeticholic acid for pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis, and Sarepta’s gene the..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms